Bridgetech Asia Limited ("BT Asia") is supporting Greater China’s need for Western healthcare by establishing itself as the leader in the transfer of US FDA approved, CE Mark and/or late-stage Western medical technology to Greater China. BT Asia's vision is to gain financial success through promoting the greatest social good and helping every Chinese consumer gain access to the world’s best medical technology.

BT Asia’s business model uses significant financial leverage while minimizing the traditional risk associated with the biotech industry. Rather than fund the discovery process, BT Asia offers biotech companies quick access to much needed clinical trial data, regulatory resources and a path to near term revenue. BT Asia obtains exclusive Greater China distribution or in-license rights for US FDA approved, CE Mark and/or later-stage products which have shown promising efficacy. In exchange for these rights, BT Asia provides clinical trial data, a revenue share on product distribution, and in some cases, a minimal licensing fee.

BT Asia’s “basket approach” to building a portfolio of US FDA approved, CE Mark and/or late-stage drugs, devices and diagnostic products mitigates the financial risks associated with concentrating investments into one product. Once exclusive Greater China distribution or in-license rights are obtained, Guangzhou Bridgetech Medicines Limited ("GBML"), a wholly foreign owned enterprise ("WFOE") established by BT Asia in China, will process regulatory approval from China’s State Food and Drug Administration ("SFDA") and distribute these products throughout China, and subsidiaries in Hong Kong and Taiwan will obtain local regulatory approval and provide sales, distribution and support.

To execute our strategy, BT Asia has assembled a seasoned international management team with extensive operations and healthcare experience. Our team enjoys valuable and longstanding relationships with leading healthcare organizations, key members of the U.S. and Greater China governments, and with the regulatory and medical communities.